|
#2
22.05.2007, 17:20
|
||||
|
||||
|
Äðóãèì çàèíòåðåñîâàííûì ëèöàì òîæå ìîæíî ïî÷èòàòü?
 
|
|
#3
22.05.2007, 20:35
|
||||
|
||||
|
Öèòàòà:
|
|
#5
07.08.2007, 00:12
|
||||
|
||||
|
Ñïàñèáî çà ñóììàðíûé ýâèäåíñ ïî ðåçèñòåíòíîñòè ê êëîïèãîäðåëþ, íî âñå æå ïîêà âîïðîñ îñòàåòñÿ îòêðûòûì - ðàöèîíàëüíåå òåñòèðîâàòü âñåõ ïàöèåíòîâ íà ýòîò ôåíîìåí (è êàêèìè ëàá. òåñòàìè?) è çàòåì ïî âûÿâëåíèþ ïîâûøàòü äîçó (îäíîêðàòíî èëè äî ïðåîäîëåíèÿ ðåçèñòåíòíîñòè?) êëîïèäîãðåëÿ èëè æå âñåì çàðÿæàòü ñðàçó ïîâûøåííóþ íàãðóçî÷íóþ è ïîâûøåííóþ ïîääåðæèâàþùóþ?
|
|
#6
29.10.2007, 13:35
|
||||
|
||||
|
The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#7
23.01.2008, 23:25
|
||||
|
||||
|
Especially for Gilarov and dav1972
Circulation. 2007 Nov 27;116(22):2531-4. Epub 2007 Nov 12.
Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
|
|
#8
04.03.2008, 18:15
|
||||
|
||||
|
Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#10
10.04.2008, 22:03
|
||||
|
||||
|
J Am Coll Cardiol. 2008 Apr 8;51(14):1404-11.
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Service de Cardiologie, Hôpital Universitaire Nord, Marseille, France. OBJECTIVES: This study evaluates the clinical impact of adjusting the loading dose of clopidogrel according to vasodilator-stimulated phosphoprotein (VASP) index in patients with clopidogrel resistance undergoing percutaneous coronary intervention (PCI). BACKGROUND: Clopidogrel resistance plays a key role in ischemic recurrence after PCI. In vitro tests of clopidogrel resistance can accurately predict major adverse cardiac events after PCI. METHODS: In this prospective, randomized, multicenter study, clopidogrel resistance was defined as a VASP index of more than 50% after a 600-mg loading dose. Patients with clopidogrel resistance undergoing coronary stenting were randomized to a control group or to the VASP-guided group, in which patients received additional bolus clopidogrel to decrease the VASP index below 50%. RESULTS: A total of 162 patients were included. The control (n = 84) and VASP-guided groups (n = 78) had similar demographic, clinical, and biological characteristics. In the VASP-guided group, dose adjustment was efficient in 67 patients (86%) and VASP index was significantly decreased (from 69.3 +/- 10 to 37.6 +/- 13.8; p < 0.001). Eight major adverse cardiac events (5%) were recorded during the 1-month follow-up, with a significantly lower rate in the VASP-guided group compared with the control group (0% vs. 10%; p = 0.007). There was no difference in the rate of major and minor bleeding (5% vs. 4%; p = 1). CONCLUSIONS: This is the first study to suggest that adjusting the clopidogrel loading dose according to platelet monitoring using the VASP index is safe and may significantly improve the clinical outcome after PCI in patients with clopidogrel resistance despite a first 600-mg loading dose.
|
|
#11
11.04.2008, 11:46
|
||||
|
||||
|
Öèòàòà:
|
|
#12
30.04.2008, 18:11
|
||||
|
||||
|
To Igor73
Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol. 2008;51;1527-1538 Kelly M. Chin, and Lewis J. Rubin [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#13
16.08.2008, 13:13
|
|||
|
|||
|
Prehospital initiation of tirofiban in patients with
ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Gilles Montalescot Mechanical reperfusion: treat well, treat on time too [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#14
23.08.2008, 16:15
|
||||
|
||||
|
?
Ìèõàèë Þðüåâè÷, ýòó ñòàòüþ èñêàëè?
Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#15
28.08.2008, 13:46
|
||||
|
||||
|
Ñïàñèáî, óâàæàåìûé Ìîäåðàòîð, çà âûäåëåíèå ýòîé òåìû. Åùå, êàê-íèáóäü ïðèäóìàòü, ÷òî áû çàêà÷åííûå äîêóìåíòû âèñåëè ìàêñèìàëüíî äîëãî.
Ä-ðó audovichenko: Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Aspirin Resistance An Underestimated Risk in Patients With Drug-Eluting Stents? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Âñå æåëàþùèì: Heart Disease and Stroke Statistics 2008 Update: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
Ëèíåéíûé âèä
